Positions

Overview

  • Strategies for hematopoietic stem cell transplantation in chronic lymphoproliferative disorders. Toxicity of hematopoietic stem cell transplantation. Population outcomes of hematologic malignancies.

    • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 Risk and outcomes of second malignant neoplasms in chronic myeloid leukemia survivors 2019
    2019 Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin 2019
    2019 Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study 2019
    2019 Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy 2019
    2018 Outcomes of fludarabine, high dose cytarabine and granulocyte-colony stimulating factor (FLAG) as re-induction for residual acute myeloid leukemia on day 14 bone marrow 2018
    2018 A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801 2018
    2018 Infectious diarrhea in autologous stem cell transplantation: high prevalence of coccidia in a South American center 2018
    2018 Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma 2018
    2017 Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma—a “real world” study 2017
    2016 Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity 2016
    2016 Mobilization of hematopoietic progenitor cells for autologous transportation: Consensus recommendations 2016
    2016 Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery 2016
    2016 Scoring system prognostic of outcome in patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome 2016
    2015 Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma 2015
    2015 Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: A center for international blood and marrow transplant research study 2015
    2015 Early mortality in multiple myeloma 2015
    2015 Fewer scans, better care 2015
    2015 Changes in the use of radiation therapy for early classical Hodgkin lymphoma in adolescents and young adults: Implications for survival and second malignancies 2015
    2015 Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma 2015
    2014 Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: Analysis of transplantation timing and modality 2014
    2014 Features and outcomes of diffuse large B-cell lymphoma of the thyroid in a large contemporary cohort 2014
    2014 Similar dynamics of intraapheresis autologous CD34+ recruitment and collection efficiency in patients undergoing mobilization with or without plerixafor 2014
    2013 Hematopoietic cell transplantation for systemic mature T-cell non-hodgkin lymphoma 2013
    2012 Association of age with fluorescence in situ hybridization abnormalities in multiple myeloma reveals higher rate of IGH translocations among older patients 2012
    2012 Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchange 2012
    2012 Pegfilgrastim-versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: Efficacy and cost analysis 2012
    2011 Beyond CD34+ cell dose: Impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function 2011
    2010 Testicular lymphoma 2010
    2009 Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myeloma 2009
    2007 Renal cell carcinoma: New developments in molecular biology and potential for targeted therapies 2007
    2007 Upstream Signaling Inhibition Enhances Rapamycin Effect on Growth of Kidney Cancer Cells 2007
    2006 Woman with a papillary pulmonary lesion and a complex renal cyst 2006
    2005 Use of complementary and alternative medicine by Brazilian oncologists 2005
    2004 Simultaneous occurrence of Hodgkin disease and tuberculosis: Report of three cases 2004
    2004 Evaluation of non-oncologist physician's knowledge and attitude towards cancer screening and preventive actions 2004
    2004 Negative results in cancer clinical trials - Equivalence or poor accrual? 2004
    2003 White coat effect in breast cancer patients undergoing chemotherapy 2003
    1995 Main variations of the extrahepatic biliary system and their application to the so-called "split-liver" transplantation technique 1995

    Principal Investigator On

  • Private Grant  awarded by CELGENE CORPORATION 2019 - 2024
  • International Myeloma Foundation Study of the Outcomes of Myeloma Patients with t(11;14) Translocation  awarded by International Myeloma Foundation 2019 - 2024
  • Private Grant  awarded by AMGEN, INC. 2018 - 2023
  • Private Grant  awarded by GlaxoSmithKline 2018 - 2023
  • Private Grant  awarded by MUNDIPHARMA 2018 - 2023
  • Private Grant  awarded by JUNO THERAPEUTICS 2018 - 2023
  • Private Grant  awarded by CELGENE INTERNATIONAL II SÀRL 2018 - 2023
  • Private Grant  awarded by AMGEN, INC. 2018 - 2023
  • Private Grant  awarded by Janssen 2018 - 2023
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2017 - 2022
  • IUAB 1677: Optimizing Post-Allogeneic Hematopoietic Cell Transplant Outcomes for Lymphoma using Ibrutinib  awarded by VANDERBILT UNIVERSITY 2017 - 2022
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2017 - 2022
  • Private Grant  awarded by CELGENE CORPORATION 2017 - 2022
  • Private Grant  awarded by ABBVIE INC 2016 - 2021
  • Private Grant  awarded by KARYOPHARM THERAPEUTICS, INC. 2015 - 2020
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2016 - 2020
  • Private Grant  awarded by ONYX PHARMACEUTICALS, INC. 2015 - 2020
  • Private Grant  awarded by ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC. - NEW 2018 - 2019
  • UAB 1324 -- A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) Versus HLA-Haploidentical Related Bone Marrow (Haplo-BM) for Patients with Hematologic Malignancies  awarded by National Marrow Donor Program 2016 - 2018
  • Private Grant  awarded by IMMUNOGEN, INC. 2017 - 2018

    • Investigator On

  • Private Grant  awarded by KITE PHARMA 2019 - 2024
  • Private Grant  awarded by MIRAGEN THERAPEUTICS INC. 2019 - 2024
  • Private Grant  awarded by Genentech 2019 - 2024
  • Private Grant  awarded by RHIZEN PHARMACEUTICALS SA 2018 - 2023
  • Private Grant  awarded by RHIZEN PHARMACEUTICALS SA 2018 - 2023
  • Private Grant  awarded by Genentech 2018 - 2023
  • Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease, BMT CTN PROTOCOL #1507  awarded by National Marrow Donor Program 2017 - 2023
  • Private Grant  awarded by PHARMACYCLICS, INC. 2018 - 2023
  • A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML  awarded by National Marrow Donor Program 2017 - 2022
  • Private Grant  awarded by ADC THERAPEUTICS SA 2019 - 2022
  • Private Grant  awarded by Genentech 2019 - 2022
  • Private Grant  awarded by INCYTE CORPORATION 2017 - 2022
  • Private Grant  awarded by FATE THERAPEUTICS, INC. 2017 - 2021
  • Private Grant  awarded by EPIZYME - NEW 2016 - 2021
  • Private Grant  awarded by JUNO THERAPEUTICS 2016 - 2021
  • Private Grant  awarded by JUNO THERAPEUTICS 2016 - 2021
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2016 - 2021
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2016 - 2021
  • Private Grant  awarded by MedImmune 2010 - 2020
  • Private Grant  awarded by MERCK SHARP & DOHME CORP 2015 - 2020
  • Molecular Characterization of Myeloma and Related Asymptomatic Precursor States  awarded by National Cancer Institute/NIH/DHHS 2014 - 2020
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2018 - 2020
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2014 - 2020
  • Southwest Oncology Group Purchase Service Agreement  awarded by Oregon Health & Science University 2015 - 2020
  • Private Grant  awarded by Genentech 2018 - 2020
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2015 - 2020
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2014 - 2019
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC 2017 - 2019
  • Private Grant  awarded by INCYTE CORPORATION 2018 - 2019
  • BMT CTN 1302- Multicenter Phase II, Double Blinded, Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma  awarded by National Marrow Donor Program 2017 - 2019
  • Prospective Observation of Cardiac Safety with Proteasome Inhibition (PROTECT)  awarded by VANDERBILT UNIVERSITY 2017 - 2019
  • Private Grant  awarded by FATE THERAPEUTICS, INC. 2016 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2012 - 2018
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2013 - 2018
  • Private Grant  awarded by Genentech 2015 - 2018
  • Private Grant  awarded by Gilead Sciences 2013 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2012 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2017 - 2018
  • Private Grant  awarded by INCYTE CORPORATION 2013 - 2018
  • Private Grant  awarded by PHARMACYCLICS, INC. 2015 - 2018
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2014 - 2018
  • Private Grant  awarded by Genentech 2016 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2014 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2016 - 2017
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2012 - 2017
  • Private Grant  awarded by ARRAY BIOPHARMA 2015 - 2016
  • Private Grant  awarded by GlaxoSmithKline 2013 - 2016
  • Private Grant  awarded by MedImmune 2012 - 2016
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2011 - 2015
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2013 - 2014

    • Education And Training

  • Doctor of Philosophy in Cell / Cellular Biology and Anatomical Sciences, University of Sao Paulo 2007
  • Doctor of Medicine, University of Sao Paulo 1999

    • Full Name

  • Luciano Costa